{"id":"NCT03930641","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration","officialTitle":"An Open-Label, Single-Arm, Multicenter, Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration to Evaluate the Safety of Brolucizumab 6 mg in Prefilled Syringe","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-23","primaryCompletion":"2019-07-02","completion":"2019-07-02","firstPosted":"2019-04-29","resultsPosted":"2020-08-03","lastUpdate":"2021-01-05"},"enrollment":34,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age Related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"RTH258","otherNames":["brolucizumab"]}],"arms":[{"label":"RTH258","type":"EXPERIMENTAL"}],"summary":"This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations of the prefilled syringe use for intravitreal injection.","primaryOutcome":{"measure":"The Safety of Brolucizumab 6 mg Delivered in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration","timeFrame":"Up to Day 31","effectByArm":[{"arm":"RTH258","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=556"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":[]}}